Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort
Authors
Keywords
National Comprehensive Cancer Network, Pancreatic Fistula, National Comprehensive Cancer Network, Induction Treatment, Locally Advanced
Journal
ANNALS OF SURGICAL ONCOLOGY
Volume 22, Issue S3, Pages 1196-1205
Publisher
Springer Nature
Online
2015-08-13
DOI
10.1245/s10434-015-4783-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pancreatic Adenocarcinoma, Version 2.2014
- (2017) Margaret A. Tempero et al. Journal of the National Comprehensive Cancer Network
- Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer
- (2015) Cristina R. Ferrone et al. ANNALS OF SURGERY
- New challenges in perioperative management of pancreatic cancer
- (2015) Francesco Puleo WORLD JOURNAL OF GASTROENTEROLOGY
- FOLFIRINOX for Locally Advanced Pancreatic Adenocarcinoma: Results of an AGEO Multicenter Prospective Observational Cohort
- (2014) L. Marthey et al. ANNALS OF SURGICAL ONCOLOGY
- Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials)
- (2014) Franck Bonnetain et al. EUROPEAN JOURNAL OF CANCER
- Neoadjuvant FOLFIRINOX Application in Borderline Resectable Pancreatic Adenocarcinoma
- (2014) Alessandro Paniccia et al. MEDICINE
- Neoadjuvant FOLFIRINOX for Borderline Resectable Pancreas Cancer: A New Treatment Paradigm?
- (2014) K. K. Christians et al. ONCOLOGIST
- Locally Advanced Pancreatic Adenocarcinoma: Reassessment of Response with CT after Neoadjuvant Chemotherapy and Radiation Therapy
- (2014) Christophe Cassinotto et al. RADIOLOGY
- Management of Borderline Resectable Pancreatic Cancer
- (2014) Matthew H.G. Katz et al. SEMINARS IN RADIATION ONCOLOGY
- Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer
- (2013) Helmut Oettle et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a French multicentre prospective evaluation of resection margins in 150 evaluable specimens
- (2013) Jean Robert Delpero et al. HPB
- Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2012) T. Seufferlein et al. ANNALS OF ONCOLOGY
- Pancreatic Ductal Adenocarcinoma
- (2012) Ioannis T. Konstantinidis et al. ANNALS OF SURGERY
- A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma
- (2012) Peter J Hosein et al. BMC CANCER
- ‘Artery-first’ approaches to pancreatoduodenectomy
- (2012) P. Sanjay et al. BRITISH JOURNAL OF SURGERY
- Annual Report to the Nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity
- (2012) Christie Eheman et al. CANCER
- Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators
- (2012) Matthew H. G. Katz et al. CANCER
- Effect of Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid or Gemcitabine vs Observation on Survival in Patients With Resected Periampullary Adenocarcinoma
- (2012) John P. Neoptolemos et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma
- (2011) Deyali Chatterjee et al. CANCER
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant therapy in pancreatic adenocarcinoma: A meta-analysis of phase II trials
- (2011) M. Mura Assifi et al. SURGERY
- The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM
- (2010) Stephen B. Edge et al. ANNALS OF SURGICAL ONCOLOGY
- Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data
- (2010) Monique Maas et al. LANCET ONCOLOGY
- Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages
- (2010) Sonja Gillen et al. PLOS MEDICINE
- Consensus Report of the National Cancer Institute Clinical Trials Planning Meeting on Pancreas Cancer Treatment
- (2009) Philip A. Philip et al. JOURNAL OF CLINICAL ONCOLOGY
- Borderline Resectable Pancreatic Cancer: The Importance of This Emerging Stage of Disease
- (2008) Matthew H.G. Katz et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now